Sweden Pulmonary Arterial Hypertension Market Outlook

sweden’s pulmonary arterial hypertension (pah) market has continued to grow in recent years, though there is still much progress to be made. the swedish national board of health and welfare estimates that currently about 1,000 patients in sweden are affected by pah. in 2018, the swedish pah market comprised four major players: actelion pharmaceuticals (sold to johnson & johnson in 2017), gilead, glaxosmithkline (gsk), and bayer ag. actelion pharmaceuticals had a major presence in the swedish pah market, with several branded and generic products. johnson & johnson followed the acquisition of actelion’s products in 2017 with commercialization of two additional pah drugs, opsumit and uptravi. gilead’s letairis (ambrisentan) and glaxosmithkline’s ventavis (iloprost) were also important players in the swedish pah market. the market is facing several challenges. despite the availability of treatments, the disease still has a mortality rate of 25% within 5 years of diagnosis, which speaks to the need for improved treatment outcomes. moreover, the cost of treatment in sweden continues to be a major impediment to access. this is primarily due to the high cost of innovative drugs, as well as pricing strategies that can make treatments unavailable to patients. to address these challenges, research on pah has been conducted in sweden. one such study conducted in 2017 aimed to understand the causes of hospitalization of patients with pah and aims to collect data that could contribute to more effective treatments. additionally, several clinical trials for pah are being conducted in sweden, which could promote knowledge and lead to more tailored treatments for patients with pah. in the near-term, the swedish pah market is likely to see sales growth driven by increased utilization of existing treatments as well as continued uptake of new treatments as they become available. in the mid- to long-term, the market could benefit from the development of targeted treatments, increased public awareness, and increased access to treatments through government subsidies and lower prices. in addition, the continued development of more personalized treatments could lead to improved outcomes for patients.